ERBB2 and breast carcinoma: Consequently, therapeutic strategies targeting HER2 have been developed and trastuzumab, a humanized monoclonal antibody (mAb) targeting the extracellular domain of HER2, has substantially improved outcomes for patients with HER2-positive (HER2+) breast cancer (9–11).